X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (114) 114
humans (108) 108
hematology (67) 67
multiple myeloma - drug therapy (67) 67
oncology (67) 67
male (65) 65
middle aged (65) 65
female (63) 63
multiple myeloma (63) 63
aged (59) 59
adult (44) 44
bortezomib (38) 38
treatment outcome (38) 38
antineoplastic combined chemotherapy protocols - therapeutic use (36) 36
aged, 80 and over (32) 32
dexamethasone - administration & dosage (29) 29
lenalidomide (28) 28
thalidomide - analogs & derivatives (28) 28
abridged index medicus (26) 26
dexamethasone (25) 25
multiple myeloma - pathology (25) 25
multiple myeloma - mortality (24) 24
thalidomide - administration & dosage (22) 22
antineoplastic combined chemotherapy protocols - adverse effects (20) 20
multiple myeloma - therapy (20) 20
survival (20) 20
chemotherapy (19) 19
recurrence (19) 19
thalidomide (19) 19
combination therapy (18) 18
plus dexamethasone (18) 18
thalidomide - adverse effects (18) 18
lenalidomide plus dexamethasone (17) 17
therapy (17) 17
cancer (16) 16
stem-cell transplantation (16) 16
antineoplastic agents - therapeutic use (15) 15
dose-response relationship, drug (15) 15
care and treatment (14) 14
hematology, oncology and palliative medicine (14) 14
myeloma (14) 14
prognosis (14) 14
retrospective studies (13) 13
drug administration schedule (12) 12
oligopeptides - administration & dosage (12) 12
research (12) 12
survival analysis (12) 12
transplantation (12) 12
antineoplastic combined chemotherapy protocols - administration & dosage (11) 11
article (11) 11
carfilzomib (11) 11
dexamethasone - adverse effects (11) 11
drug therapy (11) 11
multiple-myeloma (11) 11
transplantation, autologous (11) 11
disease-free survival (10) 10
multiple myeloma - complications (10) 10
multiple myeloma - diagnosis (10) 10
newly-diagnosed myeloma (10) 10
open-label (10) 10
single-agent carfilzomib (10) 10
stem cells (10) 10
thalidomide - therapeutic use (10) 10
antineoplastic agents - administration & dosage (9) 9
antineoplastic agents - adverse effects (9) 9
combination (9) 9
disease progression (9) 9
follow-up studies (9) 9
kaplan-meier estimate (9) 9
low-dose dexamethasone (9) 9
oligopeptides - adverse effects (9) 9
peripheral neuropathy (9) 9
survival rate (9) 9
analysis (8) 8
animals (8) 8
clinical trials and observations (8) 8
multiple myeloma - metabolism (8) 8
time factors (8) 8
trial (8) 8
autologous transplantation (7) 7
clarithromycin - administration & dosage (7) 7
clinical trials as topic (7) 7
drug resistance, neoplasm (7) 7
efficacy (7) 7
elderly-patients (7) 7
hematopoietic stem cell transplantation (7) 7
medical colleges (7) 7
phase-2 (7) 7
relapse (7) 7
angiogenesis inhibitors (6) 6
antibodies, monoclonal - therapeutic use (6) 6
boronic acids - administration & dosage (6) 6
boronic acids - therapeutic use (6) 6
cells (6) 6
clinical trials (6) 6
dexamethasone - therapeutic use (6) 6
diagnosis (6) 6
dosage and administration (6) 6
immunology (6) 6
maintenance (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JAMA, ISSN 0098-7484, 12/2017, Volume 318, Issue 21, pp. 2085 - 2086
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 13, pp. 1503 - 1512
Journal Article
JAMA - Journal of the American Medical Association, ISSN 0098-7484, 12/2017, Volume 318, Issue 21, pp. 2085 - 2086
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2015, Volume 372, Issue 2, pp. 142 - 152
Journal Article
The Lancet Oncology, ISSN 1470-2045, 10/2017, Volume 18, Issue 10, pp. 1327 - 1337
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2007, Volume 357, Issue 21, pp. 2133 - 2142
Journal Article
Clinical Advances in Hematology and Oncology, ISSN 1543-0790, 04/2012, Volume 10, Issue 4, p. 3
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2009, Volume 15, Issue 16, pp. 5250 - 5257
Journal Article
Seminars in Oncology, ISSN 0093-7754, 12/2016, Volume 43, Issue 6, pp. 709 - 711
The expanding armamentarium of novel agents used in combination to treat multiple myeloma (MM) can induce clinical responses in most newly diagnosed patients,... 
Minimal residual disease | Myeloma | Autologous transplantation | CRITERIA | IMPACT | ONCOLOGY | Multiple Myeloma - therapy | Humans | Middle Aged | Hematopoietic Stem Cell Transplantation | Male | Transplantation, Autologous | Neoplasm, Residual - therapy
Journal Article
Cancer Treatment Reviews, ISSN 0305-7372, 2015, Volume 41, Issue 10, pp. 827 - 835
Although survival outcomes have improved over the last decade for patients with multiple myeloma (MM), few patients remain free of disease and most inevitably... 
Proteasome inhibitor | Immunomodulatory drug | Multiple myeloma
Journal Article
Clinical Advances in Hematology and Oncology, ISSN 1543-0790, 09/2013, Volume 11, Issue 9, pp. 605 - 606
Journal Article
British Journal of Haematology, ISSN 0007-1048, 05/2017, Volume 177, Issue 3, pp. 404 - 413
Journal Article